WallStreetZenWallStreetZen

NASDAQ: DNLI
Denali Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for DNLI

Based on 5 analysts offering 12 month price targets for Denali Therapeutics Inc

Min Forecast
$25.00+15%
Avg Forecast
$28.60+31.55%
Max Forecast
$32.00+47.19%

Should I buy or sell DNLI stock?

Based on 5 analysts offering ratings for Denali Therapeutics Inc.

Strong Buy
Strong Buy
4 analysts 80%
Buy
1 analysts 20%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although DNLI's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates DNLI as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their DNLI stock forecasts and price targets.

DNLI stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-01-07
lockedlocked$00.00+00.00%2025-12-11
lockedlocked$00.00+00.00%2025-12-05
lockedlocked$00.00+00.00%2025-11-04
lockedlocked$00.00+00.00%2025-08-18

1 of 1

Forecast return on equity

Is DNLI forecast to generate an efficient return?

Company
-11.27%
Industry
352.12%
Market
211.34%
DNLI's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is DNLI forecast to generate an efficient return on assets?

Company
-9.89%
Industry
122.26%
DNLI is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

DNLI earnings per share forecast

What is DNLI's earnings per share in the next 3 years based on estimates from 20 analysts?

Avg 1 year Forecast
-$2.98
Avg 2 year Forecast
-$2.73
Avg 3 year Forecast
-$0.90

DNLI revenue forecast

What is DNLI's revenue in the next 3 years based on estimates from 20 analysts?

Avg 1 year Forecast
$43.7M
Avg 2 year Forecast
$165.3M
Avg 3 year Forecast
$496.5M

DNLI vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
DNLI$21.74$28.60+31.55%Strong Buy
XENE$41.01$53.50+30.46%Strong Buy
VRDN$33.00$41.89+26.94%Strong Buy
LEGN$17.50$61.11+249.21%Strong Buy
TERN$34.60$48.60+40.47%Strong Buy
View Top Biotech Stocks

Denali Therapeutics Stock Forecast FAQ

Is Denali Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: DNLI) stock is to Strong Buy DNLI stock.

Out of 5 analysts, 4 (80%) are recommending DNLI as a Strong Buy, 1 (20%) are recommending DNLI as a Buy, 0 (0%) are recommending DNLI as a Hold, 0 (0%) are recommending DNLI as a Sell, and 0 (0%) are recommending DNLI as a Strong Sell.

If you're new to stock investing, here's how to buy Denali Therapeutics stock.

What is DNLI's earnings growth forecast for 2026-2028?

(NASDAQ: DNLI) Denali Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.84%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.88%.

Denali Therapeutics's earnings in 2026 is -$498,744,000.On average, 20 Wall Street analysts forecast DNLI's earnings for 2026 to be -$436,861,602, with the lowest DNLI earnings forecast at -$530,211,859, and the highest DNLI earnings forecast at -$287,970,509. On average, 17 Wall Street analysts forecast DNLI's earnings for 2027 to be -$400,342,806, with the lowest DNLI earnings forecast at -$507,361,945, and the highest DNLI earnings forecast at -$311,069,748.

In 2028, DNLI is forecast to generate -$132,552,965 in earnings, with the lowest earnings forecast at -$416,812,929 and the highest earnings forecast at $304,909,951.

What is DNLI's revenue growth forecast for 2026-2028?

(NASDAQ: DNLI) Denali Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.92%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.08%.

Denali Therapeutics's revenue in 2026 is $0.On average, 20 Wall Street analysts forecast DNLI's revenue for 2026 to be $6,408,095,469, with the lowest DNLI revenue forecast at $1,021,206,343, and the highest DNLI revenue forecast at $24,608,388,959. On average, 17 Wall Street analysts forecast DNLI's revenue for 2027 to be $24,243,200,995, with the lowest DNLI revenue forecast at $6,048,773,978, and the highest DNLI revenue forecast at $54,044,885,461.

In 2028, DNLI is forecast to generate $72,813,200,230 in revenue, with the lowest revenue forecast at $24,045,207,520 and the highest revenue forecast at $142,707,829,982.

What is DNLI's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: DNLI) forecast ROA is -9.89%, which is lower than the forecast US Biotechnology industry average of 122.26%.

What is DNLI's Price Target?

According to 5 Wall Street analysts that have issued a 1 year DNLI price target, the average DNLI price target is $28.60, with the highest DNLI stock price forecast at $32.00 and the lowest DNLI stock price forecast at $25.00.

On average, Wall Street analysts predict that Denali Therapeutics's share price could reach $28.60 by Jan 7, 2027. The average Denali Therapeutics stock price prediction forecasts a potential upside of 31.55% from the current DNLI share price of $21.74.

What is DNLI's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: DNLI) Denali Therapeutics's current Earnings Per Share (EPS) is -$2.92. On average, analysts forecast that DNLI's EPS will be -$2.98 for 2026, with the lowest EPS forecast at -$3.62, and the highest EPS forecast at -$1.96. On average, analysts forecast that DNLI's EPS will be -$2.73 for 2027, with the lowest EPS forecast at -$3.46, and the highest EPS forecast at -$2.12. In 2028, DNLI's EPS is forecast to hit -$0.90 (min: -$2.84, max: $2.08).

What is DNLI's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: DNLI) forecast ROE is -11.27%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.